Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea.
Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.
PLoS One. 2019 Feb 26;14(2):e0212672. doi: 10.1371/journal.pone.0212672. eCollection 2019.
Radial probe endobronchial ultrasound using a guide sheath (EBUS-GS) is used to diagnose peripheral lung cancer. The aim was to identify the accuracy of molecular analysis that were performed with EBUS-GS specimens in patients with non-small cell lung cancer (NSCLC).
From December 2015 to September 2017, we retrospectively studied 91 patients with peripheral NSCLC who underwent surgery after EBUS-GS. Epidermal growth factor receptor (EGFR) mutational and anaplastic lymphoma kinase (ALK) translocation status obtained from surgical specimens served as the references.
Compared to the reference data, EGFR mutational testing of EBUS-GS specimens was in 97% agreement, and the κ coefficient was 0.931 (P< 0.001). In addition, on ALK translocation testing, the results of all 91 patients were in agreement with the reference data (concordance rate of 100%, κ coefficient 1.000; P< 0.001).
We found that EBUS-GS could be used for molecular diagnosis, such as EGFR mutational and ALK translocation status, in patients with peripheral NSCLC.
使用引导鞘的径向探头支气管内超声(EBUS-GS)用于诊断周围型肺癌。目的是确定对非小细胞肺癌(NSCLC)患者进行 EBUS-GS 标本的分子分析的准确性。
从 2015 年 12 月至 2017 年 9 月,我们回顾性研究了 91 例接受 EBUS-GS 后手术的周围型 NSCLC 患者。手术标本中表皮生长因子受体(EGFR)突变和间变性淋巴瘤激酶(ALK)易位状态作为参考。
与参考数据相比,EBUS-GS 标本的 EGFR 突变检测的一致性为 97%,κ 系数为 0.931(P<0.001)。此外,在 ALK 易位检测方面,91 例患者的所有结果均与参考数据一致(一致性率为 100%,κ 系数为 1.000;P<0.001)。
我们发现 EBUS-GS 可用于周围型 NSCLC 患者的分子诊断,例如 EGFR 突变和 ALK 易位状态。